Halozyme Therapeutics Inc.
NASDAQ · HALO·San Diego, CA·Large-cap·Approved
Enzyme-based drug delivery company with the ENHANZE (rHuPH20) technology platform enabling subcutaneous formulations of biologics across oncology and immunology. Halozyme earns royalties from major pharma partners (Roche, J&J, Pfizer, argenx) and markets proprietary oncology assets.
Decks (2)
| Title | Occasion | Date | Slides | Source |
|---|---|---|---|---|
| Halozyme First Quarter 2026 Financial & Operating Results | Earnings | May 11, 2026 | 17 | — |
| Halozyme Guidance and Business Update January 2026 | Corporate overview | January 28, 2026 | 26 | — |